Hefei Lifeon Pharmaceutical (003020.SZ): The application for listing of Pidotimod raw material drug has been accepted.

Hefei Lifeon Pharmaceutical (003020.SZ) announced that the company has received a "Notice of Acceptance" for the market application of the raw material drug, Bepidu Acid, issued by the National Medical Products Administration. The announcement indicates that Bepidu Acid is a adenosine triphosphate-citrate lyase inhibitor that reduces low-density lipoprotein cholesterol (LDL-C) by inhibiting cholesterol synthesis in the liver. The indications for Bepidu Acid preparations are: for adult patients who are unable to receive recommended statin therapy (including patients who have not used statins), to reduce the risk of myocardial infarction and coronary artery revascularization. It is suitable for patients diagnosed with cardiovascular disease, or for patients who have not been diagnosed with cardiovascular disease but have a high risk of cardiovascular events. As an adjunctive therapy to diet, used in combination with other LDL-C lowering therapies, or used alone when LDL-C lowering therapy cannot be performed simultaneously, it can reduce LDL-C levels in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia).